Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044313879> ?p ?o ?g. }
- W2044313879 endingPage "4547" @default.
- W2044313879 startingPage "4541" @default.
- W2044313879 abstract "Purpose The type 1 insulin-like growth factor 1 receptor (IGF-1R) has been implicated in the pathogenesis of the Ewing sarcoma family of tumors (ESFT). We conducted a multicenter phase II study of the fully human IGF-1R monoclonal antibody R1507 in patients with recurrent or refractory ESFT. Patients and Methods Patients ≥ 2 years of age with refractory or recurrent ESFT received R1507 at doses of 9 mg/kg intravenously one a week or 27 mg/kg intravenously every three weeks. Response was measured by using WHO criteria. Tumor imaging was performed every 6 weeks for 24 weeks and then every 12 weeks. Results From December 2007 through April 2010, 115 eligible patients from 31 different institutions were enrolled. The median age was 25 years (range, 8 to 78 years). The location of the primary tumor was bone in 57% of patients and extraskeletal in 43% of patients. A total of 109 patients were treated with R1507 9 mg/kg/wk, and six patients were treated with 27 mg/kg/3 wk. The overall complete response/partial response rate was 10% (95% CI, 4.9% to 16.5%). The median duration of response was 29 weeks (range, 12 to 94 weeks), and the median overall survival was 7.6 months (95% CI, 6 to 9.7 months). Ten of 11 responses were observed in patients who presented with primary bone tumors (P = .016). The most common adverse events of grades 3 to 4 were pain (15%), anemia (8%), thrombocytopenia (7%), and asthenia (5%). Conclusion R1507 was a well-tolerated agent that had meaningful and durable benefit in a subgroup of patients with ESFT. The identification of markers that are predictive of a benefit is necessary to fully capitalize on this approach." @default.
- W2044313879 created "2016-06-24" @default.
- W2044313879 creator A5001104743 @default.
- W2044313879 creator A5010913859 @default.
- W2044313879 creator A5016367638 @default.
- W2044313879 creator A5020992966 @default.
- W2044313879 creator A5022982759 @default.
- W2044313879 creator A5029123414 @default.
- W2044313879 creator A5038603211 @default.
- W2044313879 creator A5042484310 @default.
- W2044313879 creator A5046099119 @default.
- W2044313879 creator A5046880941 @default.
- W2044313879 creator A5051922909 @default.
- W2044313879 creator A5060114622 @default.
- W2044313879 creator A5065224999 @default.
- W2044313879 creator A5066585382 @default.
- W2044313879 creator A5068677359 @default.
- W2044313879 creator A5073906112 @default.
- W2044313879 creator A5077232908 @default.
- W2044313879 creator A5090104975 @default.
- W2044313879 date "2011-12-01" @default.
- W2044313879 modified "2023-10-17" @default.
- W2044313879 title "R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study" @default.
- W2044313879 cites W1970285990 @default.
- W2044313879 cites W2061054148 @default.
- W2044313879 cites W2072315137 @default.
- W2044313879 cites W2088227103 @default.
- W2044313879 cites W2113309935 @default.
- W2044313879 cites W2116194362 @default.
- W2044313879 cites W2126041479 @default.
- W2044313879 cites W2126812050 @default.
- W2044313879 cites W2140556790 @default.
- W2044313879 cites W2144991904 @default.
- W2044313879 cites W2152274262 @default.
- W2044313879 cites W2153229526 @default.
- W2044313879 cites W2156136395 @default.
- W2044313879 cites W2167156722 @default.
- W2044313879 cites W2172180034 @default.
- W2044313879 cites W4293241248 @default.
- W2044313879 doi "https://doi.org/10.1200/jco.2010.34.0000" @default.
- W2044313879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3236654" @default.
- W2044313879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22025149" @default.
- W2044313879 hasPublicationYear "2011" @default.
- W2044313879 type Work @default.
- W2044313879 sameAs 2044313879 @default.
- W2044313879 citedByCount "272" @default.
- W2044313879 countsByYear W20443138792012 @default.
- W2044313879 countsByYear W20443138792013 @default.
- W2044313879 countsByYear W20443138792014 @default.
- W2044313879 countsByYear W20443138792015 @default.
- W2044313879 countsByYear W20443138792016 @default.
- W2044313879 countsByYear W20443138792017 @default.
- W2044313879 countsByYear W20443138792018 @default.
- W2044313879 countsByYear W20443138792019 @default.
- W2044313879 countsByYear W20443138792020 @default.
- W2044313879 countsByYear W20443138792021 @default.
- W2044313879 countsByYear W20443138792022 @default.
- W2044313879 countsByYear W20443138792023 @default.
- W2044313879 crossrefType "journal-article" @default.
- W2044313879 hasAuthorship W2044313879A5001104743 @default.
- W2044313879 hasAuthorship W2044313879A5010913859 @default.
- W2044313879 hasAuthorship W2044313879A5016367638 @default.
- W2044313879 hasAuthorship W2044313879A5020992966 @default.
- W2044313879 hasAuthorship W2044313879A5022982759 @default.
- W2044313879 hasAuthorship W2044313879A5029123414 @default.
- W2044313879 hasAuthorship W2044313879A5038603211 @default.
- W2044313879 hasAuthorship W2044313879A5042484310 @default.
- W2044313879 hasAuthorship W2044313879A5046099119 @default.
- W2044313879 hasAuthorship W2044313879A5046880941 @default.
- W2044313879 hasAuthorship W2044313879A5051922909 @default.
- W2044313879 hasAuthorship W2044313879A5060114622 @default.
- W2044313879 hasAuthorship W2044313879A5065224999 @default.
- W2044313879 hasAuthorship W2044313879A5066585382 @default.
- W2044313879 hasAuthorship W2044313879A5068677359 @default.
- W2044313879 hasAuthorship W2044313879A5073906112 @default.
- W2044313879 hasAuthorship W2044313879A5077232908 @default.
- W2044313879 hasAuthorship W2044313879A5090104975 @default.
- W2044313879 hasBestOaLocation W20443138792 @default.
- W2044313879 hasConcept C121332964 @default.
- W2044313879 hasConcept C126322002 @default.
- W2044313879 hasConcept C141071460 @default.
- W2044313879 hasConcept C142424586 @default.
- W2044313879 hasConcept C142724271 @default.
- W2044313879 hasConcept C2778248108 @default.
- W2044313879 hasConcept C2778256501 @default.
- W2044313879 hasConcept C2909636867 @default.
- W2044313879 hasConcept C71924100 @default.
- W2044313879 hasConcept C87355193 @default.
- W2044313879 hasConcept C90924648 @default.
- W2044313879 hasConceptScore W2044313879C121332964 @default.
- W2044313879 hasConceptScore W2044313879C126322002 @default.
- W2044313879 hasConceptScore W2044313879C141071460 @default.
- W2044313879 hasConceptScore W2044313879C142424586 @default.
- W2044313879 hasConceptScore W2044313879C142724271 @default.
- W2044313879 hasConceptScore W2044313879C2778248108 @default.
- W2044313879 hasConceptScore W2044313879C2778256501 @default.
- W2044313879 hasConceptScore W2044313879C2909636867 @default.
- W2044313879 hasConceptScore W2044313879C71924100 @default.